Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Atai Life Sciences N.V. (NQ: ATAI )

1.685 +0.005 (+0.30%)
Streaming Delayed Price Updated: 10:48 AM EST, Nov 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Atai Life Sciences N.V.

< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
26 27 Next >
October Recap: Major Psychedelic Drug Stocks Declined 9.9%
In total, thePsychedelic Drug Stock Index went down 9.9% in September and is now down 64.7% YTD. 
Via Talk Markets
Revive Therapeutics, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 3.00% at $0.87 
Via Benzinga
Atai's Phase 2 Study For Treatment-Resistant Depression Completes Enrollment, Expects Results Soon
Clinical stage psychedelics company atai Life Sciences (NASDAQ: ATAI) and its majority-owned subsidiary Perception Neuroscience completed patient enrollment for their Phase 2a clinical trial assessing... 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 26, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.39% at $0.18 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 200 companies hit new 52-week lows. 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 25, 2022
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 6.24% at $10.39 
Via Benzinga
Canadian Company's New Version Of Chemo-Induced Pain Treatment Is On FDA Track
Drug delivery company IntelGenx Corp. 
Via Benzinga
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
Cannabis Category Performances Ranged From +14.4% To -4.6% This Past Week
The 5 categories in the cannabis sector perform quite differently week to week. Below is a summary of how each category performed last week, in descending order and since the end of September and since... 
Via Talk Markets
Allied, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Allied (OTC:ALID) shares closed up 10.21% at $0.53 
Via Benzinga
atai Life Sciences Announces R&D Day Agenda
From atai Life Sciences
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From October 18, 2022
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 15.76% at $0.14 
Via Benzinga
Atai Launches Phase 1 Clinical Trial On Novel Direct-To-Brain Drug Delivery Technology
Clinical stage biopharma company atai Life Sciences (NASDAQ: ATAI) announced the initiation of the Phase 1 proof-of-concept (PoC) clinical trial of intranasal INB-01, a sol-gel based, excipient ( 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  During Tuesday's session, 78 companies made new 52-week lows. 
Via Benzinga
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
From atai Life Sciences
Via GlobeNewswire
Psychedelic Stock Gainers And Losers From October 17, 2022
GAINERS: Biomind Labs (OTC:BMNDF) shares closed up 38.18% at $1.52 
Via Benzinga
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 9.12% at $0.12 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 12, 2022
GAINERS: Allied (OTC:ALID) shares closed up 48.05% at $0.48 
Via Benzinga
Novel Psychedelic Compound Show Positive Results For Opioid Use Disorder Treatment
Kratom grows in several Asian countries and has been traditionally used by local communities as a natural home remedy for pain, depression and addiction. 
Via Benzinga
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
From atai Life Sciences
Via GlobeNewswire
Numinus Wellness, Small Pharma Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 7.61% at $0.12 
Via Benzinga
Psychedelic Drugs Prove Their Worth In Clinical Trials
Novel psychedelic drugs have continuously proven their worth in clinical trials. Just recently, one company revealed that it was in the process of finalizing its Phase 1 first-in-human clinical trial... 
Via PressReach
Psychedelic Stock Gainers And Losers From October 10, 2022
GAINERS: Cybin (AMEX:CYBN) shares closed up 5.51% at $0.63 LOSERS: 
Via Benzinga
Psychedelic Drug Stocks Index Up Slightly This Week
There are 8 stocks in the munKNEE Psychedelic Drug Stocks Index and this article reveals how its constituents performed this week, in descending order, since the end of August and YTD. 
Via Talk Markets
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
Alberta Becomes The First Canadian Province To Regulate Psychedelics-Assisted Therapy 
Via Benzinga
Psychedelic Stock Gainers And Losers From October 6, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 45.41% at $0.22 
Via Benzinga
Colorado to Vote on Legalizing Psychoactives in November
Voters in Colorado will have a say in the legalization of psychedelic drugs this November as an initiative to legalize psilocybin mushrooms and other naturally occurring psychedelics appears on the... 
Via PressReach
Topics Supply Chain
Exposures Supply Chain
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease, announcing recently that it has gotten approval from Argentina’s regulators to begin a Phase ll... 
Via PressReach
Topics Cannabis
Exposures Cannabis
Scientists Are Studying Psychedelic Drug as a Possible Treatment for Alzheimer’s Disease
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – October 5, 2022 – A Toronto-based biotech firm is developing a new psychedelic medicine to cure Alzheimer’s disease,... 
Via FinancialNewsMedia
Topics Cannabis
Exposures Cannabis
atai's Phase 1 Synthetic DMT-Based Drug Clinical Trial Begins Patient Dosing
Clinical-stage biopharma company atai Life Sciences N.V. (NASDAQ: ATAI) has commenced dosing volunteers for its ongoing Phase 1 clinical study investigating its proprietary DMT-based VLS-01 for... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 18
...
26 27 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.